These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26695439)

  • 1. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
    Zahavi T; Lanton T; Divon MS; Salmon A; Peretz T; Galun E; Axelrod JH; Sonnenblick A
    Oncotarget; 2016 Jan; 7(4):4860-70. PubMed ID: 26695439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
    Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
    J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib prolongs liver regeneration after hepatic resection in rats.
    Mollbrink A; Augsten M; Hultcrantz R; Eriksson LC; Stål P
    J Surg Res; 2013 Oct; 184(2):847-54. PubMed ID: 23726434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver.
    Ella E; Heim D; Stoyanov E; Harari-Steinfeld R; Steinfeld I; Pappo O; Perlman TS; Nachmansson N; Rivkin L; Olam D; Abramovitch R; Wege H; Galun E; Goldenberg D
    Oncotarget; 2014 Nov; 5(21):10318-31. PubMed ID: 25401338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
    Stefanovic M; Tutusaus A; Martinez-Nieto GA; Bárcena C; de Gregorio E; Moutinho C; Barbero-Camps E; Villanueva A; Colell A; Marí M; García-Ruiz C; Fernandez-Checa JC; Morales A
    Oncotarget; 2016 Feb; 7(7):8253-67. PubMed ID: 26811497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1.
    Wang SH; Yeh SH; Shiau CW; Chen KF; Lin WH; Tsai TF; Teng YC; Chen DS; Chen PJ
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26206949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
    Shi JH; Liu SZ; Wierød L; Scholz H; Anmarkrud JA; Huitfeldt HS; Zhang SJ; Line PD
    J Surg Oncol; 2013 Mar; 107(4):393-401. PubMed ID: 22927239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis.
    Stoyanov E; Ludwig G; Mizrahi L; Olam D; Schnitzer-Perlman T; Tasika E; Sass G; Tiegs G; Jiang Y; Nie T; Kohler J; Schinazi RF; Vertino PM; Cedar H; Galun E; Goldenberg D
    Oncotarget; 2015 May; 6(13):11047-60. PubMed ID: 25918251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
    Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
    Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
    Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis.
    Potikha T; Stoyanov E; Pappo O; Frolov A; Mizrahi L; Olam D; Shnitzer-Perlman T; Weiss I; Barashi N; Peled A; Sass G; Tiegs G; Poirier F; Rabinovich GA; Galun E; Goldenberg D
    Hepatology; 2013 Jul; 58(1):192-204. PubMed ID: 23423643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
    Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
    Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
    Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sorafenib on murine liver regeneration.
    Hora C; Romanque P; Dufour JF
    Hepatology; 2011 Feb; 53(2):577-86. PubMed ID: 21274878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.